Business Context and Reporting Period
This Form 6-K filing by Zhengye Biotechnology Holding Limited covers the month of February 2026, with a report date of February 23, 2026. The filing addresses a corporate governance matter involving the resignation of an independent director.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a disclosure regarding board composition and does not contain financial performance data.
Material Changes
- Director Resignation: Mr. Wenbin Wang resigned from the Board of Directors and all committees (Audit, Compensation, Nominating and Corporate Governance) effective February 18, 2026, citing personal reasons.
- Regulatory Compliance: The resignation caused the Company to fall out of compliance with Nasdaq Listing Rule 5605(b)(1), which requires a majority of the board to be independent directors.
Outlook, Risks, and Management Commentary
Management states there was no disagreement between Mr. Wang and the Company regarding operations, policies, or practices. Mr. Wang has been paid all amounts due and has released the Company from all claims. To cure the Nasdaq listing deficiency, the Company intends to seek shareholder approval to appoint a new independent director at its annual general meeting scheduled for March 2026.
Key Facts for Investor Verification
- Verify the timeline for the appointment of a new independent director to restore Nasdaq compliance.
- Confirm the date and agenda of the annual general meeting in March 2026.
- Monitor for any subsequent filings regarding the status of the board vacancy.